Results

1–10 of 16 results for brolucizumab

Maximum Consecutive Fluid Free Months and Its Association With Visual and Anatomical Outcomes in nAMD: A Post-Hoc Analysis From HAWK and HARRIER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2021
Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies
David M. Brown, MD
Annual Meeting Talks
2021
Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
2021
Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy
Scott D Walter, MD, MSc
Annual Meeting Talks
2021
Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
Annual Meeting Talks
2020
Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies
David M. Brown, MD
Updates from the Field
2021
Assessing Characteristics of Patients With or Without Intraocular Inflammation (IOI) In the Brolucizumab Treatment Arms From the HAWK and HARRIER, Phase 3 Studies
Jeffrey S. Heier, MD
Updates from the Field
2020
Episode 198: Journal Club about Online Physician Reviews, Systematic Review Reliability, SCORE2 24 month Data, Brolucizumab FDA Approval
Jayanth Sridhar, MD
Member Podcasts
2019
Episode 28: Brolucizumab for wet AMD (HAWK and HARRIER) - Dr. Pravin Dugel
Keyvan Koushan, MD, FRCSC
Member Podcasts
Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials
Carl D. Regillo, MD
Annual Meeting Talks
2019